Литература.

Поставить закладку

1. Dores GM et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007;139:809-819
2. Goldin LR, Pfeiffer RM, Li X, et al. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish FamilyCancer Database. Blood 2004;104:1850-1854.
3. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998;338:1506-1514.
4. Shustik C, Mick R, Silver R, et al. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol 1988;6:7-12.
5. Montserrat E, Fontanillas M, Estape J, for the Spanish PETHEMA Group. Chronic lymphocytic leukemia treatment: an interim report of PETHEMA trials. Leuk Lymphoma 1991;5:89-92.
6. CLL Trialists’ Collaborative Group. Chemothera- peutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999;91:861-868.
7. Balducci L, Yates J. General guidelines for management of older patients with cancer. Oncology. 2000;14:221-227.
8. Eichhorst B, Goede V, Hallek, M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk. Lymphoma. 2009;50:171-178.
9. Goede V, Hallek M. [Elderly patients in clinical trials: new fitness-adapted concepts]. Der Internist. 2007;48(11):1232-1237.
10. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
11. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-80.
12. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. In: Hematology 2004: American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2004:163-183.
13. Hallek M, Fischer K, Fingerle-Rowson G, et. al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet. 2010;376(9747):1164-74.
14. Стадник Е.А., Никитин Е.А., Бидерман Б.В., и соавт. Ретроспективное сравнение эффективности и токсичности режимов FC и FCR у первичных больных В-клеточным хроническим лимфолейкозом. Онкогематология. 2008;1-2:39-46
15. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750-7.
16. Catovsky D, Richards S, Matutes E, et. al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370(9583):230-9.
17. Eichhorst BF, Busch R, Hopfinger G, et. al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885-91.
18. Eichhorst B, Busch R, Stilgenbauer S, et.al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114(16):3382 - 3391
19. Catovsky D, Else M, Richards S. Chlorambucil--still not bad: a reappraisal. Clin Lymphoma Myeloma Leuk. 2011;11 Suppl 1:S2-6.
20. J. A. Woyach, A.S. Ruppert, B. Peterson, et.al. Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies. ASH Annual Meeting Abstracts 2011;118:289
21. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine versus chlorambucil as first-line treatment in B-cell chronic lymphocytic leukemia: an updated analysis from an international phase III study. Blood. 2008;112:728
22. Hillmen P, Gribben J, Follows G et al. Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study. Blood 2010;116:697
23. Foon KA, Boyiadzis M, Land R. et al. Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia. J Clin Oncol 2009;27:498-503.
24. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-8.
25. Oscier D, Fegan C, Hillmen P, et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol. 2004;125:294-317.
26. Hallek M, Stahel RA, Greil R. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia. Ann Oncol. 2005;16(suppl 1):i50-i51.
27. Keating MJ, O’Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43:1755-1762.
28. Dreger P, Corradini P, Kimby E, et.al. Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1):12-7.
29. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281
30. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood. 2002;99:3554-3561
31. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial. J Clin Oncol. 2005;23:7024-7031
32. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood. 2009;114:89(abstr 205).
33. O’Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Advances in Hematol Oncol. 2011;9(1):22-31
34. Bosch F, Abrisqueta P, Villamor N. et al. Rituximab maintenance In patients with chronic lymphocytic leukemia (CLL) after upfront treatment with rituximab plus fludarabine, cyclophosphamide, and mitoxantrone (R-FCM): final results of a multicenter phase II trial on behalf of the Spanish CLL Study Group (GELLC). Blood (ASH Annual Meeting Abstracts). 2011; 118:Abstract 293
35. Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008;22(11):2048-53.
36. Dungarwalla M, Evans SO, Riley U, et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica. 2008;93(3):475-6.
37. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-1765
38. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002;119:976-84.
39. Hallek M, Cheson BD, Catovsky D, et.al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-56.
40. Rawstron AC, Villmor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukemia. Leukemia. 2007;21(5):956-964.
41. Луговская С.А., Почтарь М.Е., Наумова Е.В. Диагностика минимальной остаточной болезни при В-клеточном хроническом лимфолейкозе методом

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница